(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 February 2007 (08.02.2007)

PCT

(10) International Publication Number
WO 2007/015167 A3

(51) International Patent Classification:
A61K 39/39 (2006.01) *A61K 39/29* (2006.01)

(21) International Application Number:
PCT/IB2006/002581

(22) International Filing Date: 2 August 2006 (02.08.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0515906.6	2 August 2005 (02.08.2005)	GB
0522599.0	4 November 2005 (04.11.2005)	GB
0523923.1	24 November 2005 (24.11.2005)	GB

(71) Applicant *(for all designated States except US)*: **NOVARTIS VACCINES AND DIAGNOSTICS SRL** [IT/IT]; Via Fiorentina 1, I-53100 Siena (IT).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **CONTORNI, Mario** [IT/IT]; Novartis Vaccines and Diagnostics SRL, Via Fiorentina 1, I-53100 Siena (IT).

(74) Agent: **MARSHALL, Cameron, John**; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
3 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REDUCING INTERFERENCE BETWEEN OIL-CONTAINING ADJUVANTS AND SURFACTANT-CONTAINING ANTIGENS

(57) Abstract: Inclusion of fatty adjuvants in vaccine compositions can cause difficulties with certain antigenic components, particularly with antigens that include a surfactant component. A method for preparing an immunogenic composition comprising an antigen and a fatty adjuvant involves purification of the antigen substantially in the absence of surfactant. Where surfactants cannot be avoided, the following are combined: (i) an antigen component that includes a surfactant and (ii) a fatty adjuvant component, to give a composition in which the weight ratio of said fatty adjuvant to said surfactant is less than 1000:1.

WO 2007/015167 A3